share_log

Aditxt | 8-K/A: Current report (Amendment)

Aditxt | 8-K/A: Current report (Amendment)

Aditxt | 8-K/A：重大事件(修正)
美股SEC公告 ·  2024/09/05 21:22

Moomoo AI 已提取核心信息

Aditxt Inc. has filed pro forma consolidated financial statements reflecting its acquisitions of Evofem Biosciences and Appili Therapeutics. The pro forma statements show combined assets of $168.5 million and total liabilities of $63.7 million as of June 30, 2024.The transactions include Aditxt's acquisition of Appili through its subsidiary Adivir, where Appili shareholders will receive 0.002745004 Aditxt shares and $0.0467 in cash per Appili share. For Evofem, the consideration includes $91.6 million in convertible preferred stock, $1.8 million cash payment to stockholders, and assumption of $13 million in senior secured notes.The pro forma consolidated statement shows a net loss of $30.2 million for the six months ended June 30, 2024. The preliminary purchase price allocation resulted in goodwill of $134.8 million and intangible assets of $6.3 million. Management notes these pro forma statements are preliminary and subject to refinement as additional fair value information becomes available within one year of closing.
Aditxt Inc. has filed pro forma consolidated financial statements reflecting its acquisitions of Evofem Biosciences and Appili Therapeutics. The pro forma statements show combined assets of $168.5 million and total liabilities of $63.7 million as of June 30, 2024.The transactions include Aditxt's acquisition of Appili through its subsidiary Adivir, where Appili shareholders will receive 0.002745004 Aditxt shares and $0.0467 in cash per Appili share. For Evofem, the consideration includes $91.6 million in convertible preferred stock, $1.8 million cash payment to stockholders, and assumption of $13 million in senior secured notes.The pro forma consolidated statement shows a net loss of $30.2 million for the six months ended June 30, 2024. The preliminary purchase price allocation resulted in goodwill of $134.8 million and intangible assets of $6.3 million. Management notes these pro forma statements are preliminary and subject to refinement as additional fair value information becomes available within one year of closing.
Aditxt公司已提交了包含Evofem Biosciences和Appili Therapeutics收购的临时合并基本报表。这些临时报表显示，截至2024年6月30日，合并资产为16850万美元，总负债为6370万美元。交易包括Aditxt通过其子公司Adivir收购Appili，Appili的股东将获得每股Appili 0.002745004股Aditxt股份和0.0467美元现金。对于Evofem，交易包括9160万美元的可转换优先股、180万美元的现金支付给股东，以及承担1300万美元的高级担保票据。临时合并报表显示截至2024年6月30日的六个月内净损失为3020万美元。初步购买价格分配导致商誉为13480万美元，无形资产为630万美元。管理层指出，这些临时报表为初步数据，并需根据在关闭一年内获得的附加公允价值信息进行修订。
Aditxt公司已提交了包含Evofem Biosciences和Appili Therapeutics收购的临时合并基本报表。这些临时报表显示，截至2024年6月30日，合并资产为16850万美元，总负债为6370万美元。交易包括Aditxt通过其子公司Adivir收购Appili，Appili的股东将获得每股Appili 0.002745004股Aditxt股份和0.0467美元现金。对于Evofem，交易包括9160万美元的可转换优先股、180万美元的现金支付给股东，以及承担1300万美元的高级担保票据。临时合并报表显示截至2024年6月30日的六个月内净损失为3020万美元。初步购买价格分配导致商誉为13480万美元，无形资产为630万美元。管理层指出，这些临时报表为初步数据，并需根据在关闭一年内获得的附加公允价值信息进行修订。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Nkarta
    NKTX
    -- 1.970
    Soleno Therapeutics
    SLNO
    -- 67.3900
    NuCana
    NCNA
    -- 1.0700
    ImmunityBio
    IBRX
    -- 3.360
    Marker Therapeutics
    MRKR
    -- 1.3700
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日